Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1962 2
1963 1
1964 2
1965 1
1966 3
1967 3
1968 4
1970 4
1971 7
1972 2
1973 2
1974 3
1975 2
1976 2
1977 10
1978 10
1979 7
1980 11
1981 15
1982 18
1983 23
1984 29
1985 23
1986 29
1987 44
1988 50
1989 47
1990 43
1991 52
1992 56
1993 75
1994 69
1995 75
1996 96
1997 126
1998 147
1999 225
2000 275
2001 281
2002 335
2003 357
2004 439
2005 482
2006 563
2007 648
2008 713
2009 828
2010 986
2011 1254
2012 1365
2013 1412
2014 1490
2015 1612
2016 1503
2017 1593
2018 1605
2019 1677
2020 1910
2021 2010
2022 1778
2023 1722
2024 1675
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26,649 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab for Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. Among authors: park yh. N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549. N Engl J Med. 2020. PMID: 32101663 Clinical Trial.
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. Among authors: park yh. N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651. N Engl J Med. 2022. PMID: 35139274 Clinical Trial.
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kümmel S, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Im SA, Untch M, Fasching PA, Mouret-Reynier MA, Foukakis T, Ferreira M, Cardoso F, Zhou X, Karantza V, Tryfonidis K, Aktan G, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. Among authors: park yh. N Engl J Med. 2024 Nov 28;391(21):1981-1991. doi: 10.1056/NEJMoa2409932. Epub 2024 Sep 15. N Engl J Med. 2024. PMID: 39282906 Clinical Trial.
Dietary pro-oxidant therapy by a vitamin K precursor targets PI 3-kinase VPS34 function.
Swamynathan MM, Kuang S, Watrud KE, Doherty MR, Gineste C, Mathew G, Gong GQ, Cox H, Cheng E, Reiss D, Kendall J, Ghosh D, Reczek CR, Zhao X, Herzka T, Špokaitė S, Dessus AN, Kim ST, Klingbeil O, Liu J, Nowak DG, Alsudani H, Wee TL, Park Y, Minicozzi F, Rivera K, Almeida AS, Chang K, Chakrabarty RP, Wilkinson JE, Gimotty PA, Diermeier SD, Egeblad M, Vakoc CR, Locasale JW, Chandel NS, Janowitz T, Hicks JB, Wigler M, Pappin DJ, Williams RL, Cifani P, Tuveson DA, Laporte J, Trotman LC. Swamynathan MM, et al. Among authors: park y. Science. 2024 Oct 25;386(6720):eadk9167. doi: 10.1126/science.adk9167. Epub 2024 Oct 25. Science. 2024. PMID: 39446948
LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation.
Sung E, Ko M, Won JY, Jo Y, Park E, Kim H, Choi E, Jung UJ, Jeon J, Kim Y, Ahn H, Choi DS, Choi S, Hong Y, Park H, Lee H, Son YG, Park K, Won J, Oh SJ, Lee S, Kim KP, Yoo C, Song HK, Jin HS, Jung J, Park Y. Sung E, et al. Among authors: park y. Mol Ther. 2022 Aug 3;30(8):2800-2816. doi: 10.1016/j.ymthe.2022.05.003. Epub 2022 May 6. Mol Ther. 2022. PMID: 35526096 Free PMC article.
Current Barriers to Clinical Liver Xenotransplantation.
Cross-Najafi AA, Lopez K, Isidan A, Park Y, Zhang W, Li P, Yilmaz S, Akbulut S, Ekser B. Cross-Najafi AA, et al. Among authors: park y. Front Immunol. 2022 Feb 23;13:827535. doi: 10.3389/fimmu.2022.827535. eCollection 2022. Front Immunol. 2022. PMID: 35281047 Free PMC article. Review.
Solitary Tracheal Papilloma.
Ko Y, Kim C, Park YB. Ko Y, et al. Among authors: park yb. Am J Respir Crit Care Med. 2020 Aug 15;202(4):e88-e89. doi: 10.1164/rccm.201911-2147IM. Am J Respir Crit Care Med. 2020. PMID: 32352835 No abstract available.
Intermittent Fasting: Current Evidence in Clinical Practice.
Kang SH, Park YS, Ahn SH, Kim HH. Kang SH, et al. Among authors: park ys. J Obes Metab Syndr. 2020 Jun 30;29(2):81-83. doi: 10.7570/jomes20022. J Obes Metab Syndr. 2020. PMID: 32400147 Free PMC article. No abstract available.
26,649 results
You have reached the last available page of results. Please see the User Guide for more information.